Search Results
Jun 11, 2026, 08:30 ET CME Group to Expand Equity Index Suite with Launch of Four New E-mini Futures Contracts
offering futures contracts on the Morningstar US Total Market Index," said Amelia Furr, President of Morningstar Indexes. "With our acquisition of the CRSP Market Indexes earlier this year and our upcoming rebrand of this series to reflect the Morningstar name, we are proud to open our high-quality equity
More news about: CME Group
Jun 10, 2026, 16:55 ET CME Group and Morningstar Announce Exclusive Index Derivatives Licensing Agreement
advisors in navigating investment opportunities across all major asset classes, styles, and strategies. In February 2026, the acquisition of CRSP brought the CRSP Market Indexes – benchmarks for over $3 trillion in US equities – into the Morningstar Indexes family. Additionally, CRSP's Research Data Products,
More news about: CME Group; Morningstar, Inc.
May 14, 2026, 09:00 ET A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
reference point on the broader aging-biology therapeutics universe that Avaí Bio's α-Klotho program sits within.CRISPR Therapeutics AG (NASDAQ: CRSP) has continued to expand its CRISPR/Cas9 gene-editing platform across multiple therapeutic verticals — including the autologous and allogeneic cell
More news about: Equity Insider
Apr 29, 2026, 09:00 ET Vanguard to Update Names of U.S. Equity Index Funds Tracking Morningstar Indexes
VALLEY FORGE, Pa., April 29, 2026 /PRNewswire/ -- Following Morningstar's rebranding of the CRSP Market Indexes to Morningstar Indexes, Vanguard today announced upcoming changes to the names of multiple Vanguard U.S. equity index funds tracking
More news about: Vanguard
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
(NASDAQ: VRTX) demonstrated what that looks like at scale. The company's gene-edited cell therapy Casgevy — developed with CRISPR Therapeutics (NASDAQ: CRSP) — became the world's first approved CRISPR-based treatment, now available for sickle cell disease and transfusion-dependent beta-thalassemia. Vertex
More news about: Equity Insider
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
forefront of this expansion include Oncolytics Biotech (NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR).
More news about: Equity Insider
Jan 02, 2026, 13:29 ET Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
pipelines of Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), CRISPR Therapeutics (NASDAQ: CRSP), Prime Medicine, Inc. (NASDAQ: PRME), and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
More news about: Equity Insider
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
convergence include Avant Technologies, Inc. (OTCQB: AVAI), Beam Therapeutics Inc. (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), and Schrödinger, Inc. (NASDAQ: SDGR).
More news about: Equity Insider
Sep 18, 2025, 08:45 ET Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
markets this week include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech SE (NASDAQ: BNTX), Bristol Myers Squibb Company (NYSE: BMY).
More news about: MarketNewsUpdates